Boston Scientific CorporationBSXNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +22.44% | +20.93% | +22.84% | +20.34% | +15.90% |
| Gross Profit Growth | +15.53% | +23.74% | +32.46% | +33.76% | +47.40% |
| EBITDA Growth | +21.02% | +23.68% | +68.35% | +29.30% | -10.74% |
| Operating Income Growth | +5.56% | +39.13% | +9.64% | +55.79% | +104.75% |
| Net Income Growth | +12.30% | +36.44% | +144.75% | +60.98% | +18.02% |
| EPS Growth | +11.60% | +35.36% | +145.12% | +60.13% | +17.22% |
| EPS Diluted Growth | +11.28% | +35.11% | +142.79% | +58.58% | +18.48% |
| Weighted Average Shares Growth | +0.61% | +0.60% | +0.54% | +0.61% | +0.58% |
| Weighted Average Shares Diluted Growth | +0.90% | +0.77% | +0.61% | +0.54% | +0.38% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +52.14% | +229.88% | +58.18% | +34.03% | -6.32% |
| Free Cash Flow Growth | +68.55% | +0.00% | +66.57% | +66.48% | -12.90% |
| Receivables Growth | +14.81% | +16.88% | +17.29% | +13.07% | +14.39% |
| Inventory Growth | +13.12% | +11.95% | +9.70% | +6.10% | +4.77% |
| Asset Growth | +12.12% | +9.47% | +11.99% | +12.16% | +10.86% |
| Book Value per Share Growth | +12.23% | +10.81% | +9.46% | +12.29% | +10.68% |
| Debt Growth | +17.44% | +6.43% | +9.98% | +7.00% | +11.40% |
| R&D Expense Growth | +26.72% | +21.04% | +37.34% | +26.29% | +23.70% |
| SG&A Expenses Growth | +16.90% | +17.08% | +18.67% | +11.46% | +13.77% |